TG Therapeutics announces that Briumvi's late-stage ENHANCE study met its goal, supporting a potential single-infusion ...

TG Therapeutics remains a Strong Buy as BRIUMVI drives robust revenue growth and pipeline expansions. Learn more about TGTX ...

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter An announcement from TG Therapeutics ( (TGTX)) is now available. On May 27, 2026, TG ...

TG Therapeutics (TGTX) announced on Wednesday that its Phase 3 ENHANCE trial evaluating a consolidated single-infusion ...

TG Therapeutics gains on strong Briumvi sales growth, higher 2026 revenue guidance and advancing late-stage studies in RMS.

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being ...

Investors in TG Therapeutics Inc (Symbol: TGTX) saw new options become available this week, for the May 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to ...

This multiple sclerosis treatment stock is in a handle of a long cup base. It recently raised its 2026 revenue forecast.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...